Your browser doesn't support javascript.
loading
A simplified cell-based assay to identify coronavirus 3CL protease inhibitors
Samuel J Resnick; Sho Iketani; Seo Jung Hong; Arie Zask; Hengrui Liu; Sungsoo Kim; Schuyler Melore; Manoj S Nair; Yaoxing Huang; Nicholas E S Tay; Tomislav Rovis; Hee Won Yang; Brent R Stockwell; David D Ho; Alejandro Chavez.
Afiliação
  • Samuel J Resnick; Columbia University Irving Medical Center
  • Sho Iketani; Columbia University Irving Medical Center
  • Seo Jung Hong; Columbia University Irving Medical Center
  • Arie Zask; Columbia University
  • Hengrui Liu; Columbia University
  • Sungsoo Kim; Columbia University Irving Medical Center
  • Schuyler Melore; Columbia University Irving Medical Center
  • Manoj S Nair; Columbia University Irving Medical Center
  • Yaoxing Huang; Columbia University Irving Medical Center
  • Nicholas E S Tay; Columbia University
  • Tomislav Rovis; Columbia University
  • Hee Won Yang; Columbia University Irving Medical Center
  • Brent R Stockwell; Columbia University
  • David D Ho; Columbia University Irving Medical Center
  • Alejandro Chavez; Columbia University Irving Medical Center
Preprint em En | PREPRINT-BIORXIV | ID: ppbiorxiv-272864
Artigo de periódico
Um artigo publicado em periódico científico está disponível e provavelmente é baseado neste preprint, por meio do reconhecimento de similaridade realizado por uma máquina. A confirmação humana ainda está pendente.
Ver artigo de periódico
ABSTRACT
We describe a mammalian cell-based assay capable of identifying coronavirus 3CL protease (3CLpro) inhibitors without requiring the use of live virus. By enabling the facile testing of compounds across a range of coronavirus 3CLpro enzymes, including the one from SARS-CoV-2, we are able to quickly identify compounds with broad or narrow spectra of activity. We further demonstrate the utility of our approach by performing a curated compound screen along with structure-activity profiling of a series of small molecules to identify compounds with antiviral activity. Throughout these studies, we observed concordance between data emerging from this assay and from live virus assays. By democratizing the testing of 3CL inhibitors to enable screening in the majority of laboratories rather than the few with extensive biosafety infrastructure, we hope to expedite the search for coronavirus 3CL protease inhibitors, to address the current epidemic and future ones that will inevitably arise.
Licença
cc_by_nc_nd
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-BIORXIV Idioma: En Ano de publicação: 2020 Tipo de documento: Preprint
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-BIORXIV Idioma: En Ano de publicação: 2020 Tipo de documento: Preprint